Clinical Trial Update: Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing nalmefene to naloxone for recurrent respiratory depression after opioid overdose has been withdrawn from the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Overdose

Drugs mentioned

• Nalmefene (nalmefene)
• Naloxone (Naloxone)

Snippet

Sponsor: University of New Mexico | Conditions: Opioid Overdose, Opiate Overdose | Phase 3 | Status: WITHDRAWN